double-skinned crabsVietnamese crab exporter
Advertisement
Advertisement
TOPIC

New medical drugs

New medical drugs
Latest news and updates on medical drug research and breakthroughs.
Commercial success of drugs in China does not guarantee clinical success in overseas markets, according to analysts. Photo: Shutterstock
Biomedicine: Companies

Chinese biotech faces reality check as ArriVent drug failure sinks stock in US

US-listed ArriVent lost nearly half its value after a Chinese-licensed cancer drug failed a late-stage trial.

Biomedicine: Companies

AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech

IPO

China’s tech IPOs weigh Hong Kong vs the mainland. But how much does it matter?

videocam
Biomedicine: Policy

Biomedicine powerhouse: China targets quarter of global first-in-class drugs

New five-year plan aims to turn the sector into a pillar industry by 2030, driven by breakthroughs in technologies across critical fields.

The plan sets 10 targets, including requiring large pharmaceutical enterprises to generate combined revenue of no less than 3.5 trillion yuan. Photo: Shutterstock
Biomedicine: Companies

GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.

4
Science

US, China trials suggest a single nanodrug shot might stop bad cholesterol forever

Separate trials using CRISPR and base editing to silence lipid genes show drastic drops in LDL-C without daily medication.

videocam
Advertisement
Advertisement
Advertisement
Hong Kong stock market

China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers.

China’s biopharmaceutical firms are increasingly looking to compete directly on the global market. Photo: Shutterstock
Medicine

Overseas licensing has helped fuel China’s biotech profits. Will it last?

Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.

videocam
Science

Chinese ‘yeast factory’ boosts cancer drug production by 1,000 times

Turning point comes from cross-disciplinary collaboration, including across plant biochemistry, synthetic biology and protein engineering.

videocam
China’s private sector

China’s drug firms set to compete on the world stage, analysts say

Amid systemic efficiency and a wave of innovation, the country’s biotech sector is expanding at a pace that has caught the market off guard.

4
With an efficiency edge that transcends simple cost advantages, China is set to see the emergence of a home-grown drug giant capable of competing with global players. Photo: Shutterstock
China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.

Clara Chan Ka-chai, CEO of Hong Kong Investment Corporation (HKIC) Photo: Enoch Yiu
China economy

Outside In | China’s export success is a by-product of self-reliance

But while the export surge is an accidental consequence of self-sufficiency and competitive manufacturers, the solution is not protectionism.

videocam
7
US-China trade war

Record Chinese biotech out-licensing meets rising US scrutiny

Surging cross-border deals out of China are running headlong into intensifying US national security fears.

videocam
22
Banking & finance

Healthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listing

Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.

Axiom Biosciences joins a swelling roster of healthcare firms seeking IPO approval in Hong Kong. Photo: Shutterstock
China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

Home-grown therapies account for 80 per cent of approvals in first six months of the year.

videocam
In addition to surging novel drug development, China’s cross-border deals with global giants show no sign of abating. Photo: Shutterstock
United States

Lab monkey prices soar as China’s biotech boom fuels windfall for breeders

In the first six months to June 30, there were 81 cross-border deals for innovative medicines worth a combined record of US$110 billion.

China’s private sector

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

Advertisement
Advertisement
Advertisement
China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

Chinese pharmaceutical companies may expand into international markets in the coming years. Photo: Shutterstock
China manufacturing

China extols potential of AI in guideline on marine biopharmaceuticals

Ministry of Natural Resources urges research institutions and drug makers to use the technology to speed up the development of new drugs.

Biomedicine: Companies

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

videocam
Science

Chinese team uses supercomputer to cut drug screening time from years to seconds

AI platform that can screen vast library of chemical compounds opens up new frontiers in fight against cancer and infectious diseases.

videocam
Innovative drug research and development typically takes more than 10 years to yield results. Photo: Shutterstock
Science

Does China’s Jiuzhang 4.0 computer herald the age of quantum supremacy?

New programmable photonic quantum computing prototype completed a complex calculation in microseconds, developers say.

A partial view of China’s new photonic quantum computing prototype, Jiuzhang 4.0. Photo: Xinhua
United States

Trump says US Food and Drug Commissioner Marty Makary is out

The FDA chief’s departure follows weeks of intensifying pressure from powerful Republicans, anti-abortion groups and others.

China’s private sector

How China’s ‘landmark’ drug pricing guidelines could be a boon for biotech

State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.

India

Opinion | Asia’s flood of cheap Ozempic generics opens gates to weight-loss abuse

Cheaper semaglutides as patent ends is good news for diabetics. But lax regulation also means a risk of abuse by those desperate to lose weight.

videocam
An advert for Eli Lilly’s obesity awareness campaign is seen on a building in Gurugram, India, on December 16. Photo: Reuters
Biomedicine: Companies

China biotech deals hit record as innovative drugs draw global interest

Deals reach US$60 billion in first quarter after analysts say Chinese biotech firms have shown substantial technological advancements.

The US$60 billion deal value represents a 73 per cent jump from the same period a year earlier. Photo: Shutterstock
China’s private sector

Rights to antibody drug from China’s Keymed change hands in US acquisition

Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.

China’s private sector

Wave of Chinese biotech deals builds with US$1.2 billion Harbour BioMed pact

Deal involving an antibody asset ‘goes beyond a traditional licensing transaction’, founder and CEO says.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement